Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-059 in recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma
2014-003574-16Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 cohorts), sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Jan 2015; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2014-003574-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003574-16.